Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7709887 | 1.00 | OPRD1 (0.31) | OPRD1 | |
| SCHEMBL7708823 | 0.88 | OPRD1 (0.31) | OPRD1 | |
| SCHEMBL1173784 | 0.87 | OPRD1 (0.33) | OPRD1 | |
| SCHEMBL7709471 | 0.82 | ESR1 (0.32) | — | |
| SCHEMBL15467849 | 0.82 | ESR1 (0.32) | — | |
| SCHEMBL1173154 | 0.78 | OPRD1 (0.34) | OPRD1 | |
| SCHEMBL1173155 | 0.78 | OPRD1 (0.34) | OPRD1 | |
| SCHEMBL7710730 | 0.76 | BACE1 (0.36) | — | |
| SCHEMBL2591841 | 0.76 | BACE1 (0.36) | — | |
| SCHEMBL14760385 | 0.76 | KDM1A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566855-B1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-05-21 | — | — | EP | disclosed |
| US-8673894-B2 | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | BACE2, BACE1, PSEN2 | OPRD1 801/4885 |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | OPRD1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.